LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

LLY

1,091.31

+2.27%↑

JNJ

224.22

+0.46%↑

ABBV

219.21

+2.9%↑

UNH

383.21

+2.17%↑

MRK

115.28

-0.64%↓

Strona główna・Stock List・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Open

SectorHealthcare

155.43 1.89

Buy Sell

Overview

Share price change

24h

Current

Min

151.1

Max

155.35

Key metrics
By Trading Economics
Income	-89M -454M
EPS	-2.29
Employees	883
EBITDA	-92M -441M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+21.37% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	3.4B 35B
Previous open	153.54
Previous close	155.43

News Sentiment

By Acuity

50%

147 / 344 Ranking in Healthcare

REVOLUTION Medicines Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 sty 2026, 11:10 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 sty 2026, 20:13 UTC

Major Market Movers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 paź 2025, 18:13 UTC

Major Market Movers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 sty 2026, 09:55 UTC

Hot Stocks

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 sty 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 sty 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 sty 2026, 19:30 UTC

Acquisitions, Mergers, Takeovers

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 14:54 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 sty 2026, 10:54 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 sty 2026, 14:49 UTC

Acquisitions, Mergers, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 sty 2026, 12:38 UTC

Acquisitions, Mergers, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 sty 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 sty 2026, 20:29 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 sty 2026, 19:48 UTC

Acquisitions, Mergers, Takeovers

Revolution Has Market Value of Around $16B -- WSJ

7 sty 2026, 19:48 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- WSJ

7 sty 2026, 19:48 UTC

Acquisitions, Mergers, Takeovers

Deal May Come Soon, Sources Say -- WSJ

7 sty 2026, 19:48 UTC

Acquisitions, Mergers, Takeovers

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Peer Comparison

Price change

REVOLUTION Medicines Inc Forecast

Price Target

By TipRanks

21.37% upside

12 Months Forecast

Average 183.65 USD 21.37%

High 263 USD

Low 140 USD

Based on 21 Wall Street analysts offering 12 month price targets forREVOLUTION Medicines Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

Buy

Hold

Sell

Based on 21 analysts giving stock ratings to REVOLUTION Medicines Inc - Dist in the past 3 months.

Sentiment

By Acuity

147 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.